{"id":"NCT01366638","sponsor":"Janssen Pharmaceutical K.K.","briefTitle":"A Study of TMC435 in Participants With Genotype 1 Hepatitis C Virus (HCV) Infection","officialTitle":"A Phase III, Open-Label Study in Japan to Assess the Efficacy and Safety of TMC435 as Part of a Treatment Regimen Including Peginterferon Alfa-2b and Ribavirin in Hepatitis C, Genotype 1 Infected Subjects","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2011-05","primaryCompletion":"2012-11","completion":"2012-11","firstPosted":"2011-06-06","resultsPosted":"2014-01-20","lastUpdate":"2014-05-05"},"enrollment":79,"design":{"allocation":"NON_RANDOMIZED","model":"PARALLEL","masking":"NONE","primaryPurpose":"TREATMENT"},"conditions":["Hepatitis C, Chronic"],"interventions":[{"type":"DRUG","name":"TMC435","otherNames":[]},{"type":"DRUG","name":"Peginterferon alfa-2b (pegIFN alfa-2b)","otherNames":["PEGINTRON"]},{"type":"DRUG","name":"Ribavirin (RBV)","otherNames":["REBETOL"]}],"arms":[{"label":"Treatment-Naive: TMC435 100 mg 12 Wks+PR 24/48","type":"EXPERIMENTAL"},{"label":"Prior Relapser: TMC435 100 mg 12 Wks+PR 24/48","type":"EXPERIMENTAL"},{"label":"Prior Non-Responder: TMC435 100 mg 12 Wks+PR 48","type":"EXPERIMENTAL"}],"summary":"The purpose of this study is to evaluate the efficacy and safety of TMC435 in combination with peginterferon alfa-2b and ribavirin in chronic genotype 1 hepatitis C virus (HCV)-infected participants who are treatment-naive or treatment-experienced (prior relapser or non-responder to Interferon-based therapy) in Japan.","primaryOutcome":{"measure":"The Percentage of Participants With a Sustained Virologic Response 12 Weeks After the Actual End of Treatment (SVR12)","timeFrame":"Week 36 or 60","effectByArm":[{"arm":"Treatment-Naive: TMC435 100 mg 12 Wks+PR 24/48","deltaMin":91.7,"sd":null},{"arm":"Prior Relapser: TMC435 100 mg 12 Wks+PR 24/48","deltaMin":100,"sd":null},{"arm":"Prior Non-Responder: TMC435 100 mg 12 Wks+PR 48","deltaMin":38.5,"sd":null}],"pValues":[]},"eligibility":{"minAge":"20 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":3,"exclusionCount":4},"locations":{"siteCount":11,"countries":["Japan"]},"refs":{"pmids":[],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":1,"n":24},"commonTop":["Pyrexia","White blood cell count decreased","Anaemia","Malaise","Headache"]}}